CRABP2 and neoplasm: In some PDACs, high CRABP2/low FABP5 expression correlates with retinoic acid sensitivity and anti-tumour effects. Other studies show CRABP2 is consistently overexpressed in PDAC, associated with poor prognosis, recurrence, and resistance to gemcitabine.